SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported)
May 13, 2011
INOVIO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
1787 Sentry Parkway West
Building 18, Suite 400
Blue Bell, Pennsylvania
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (267) 440-4200
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Item 5.07.||Submission of Matters to a Vote of Security Holders.|
The Company held its 2011 Annual Meeting of Stockholders on May 13, 2011. The following are the voting results for each matter voted upon:
Proposal 1: The election of the following nominees as directors of the Company to serve until the Companys 2012 Annual Meeting of Stockholders and until their successors are elected.
Avtar S. Dhillon
J. Joseph Kim
Simon X. Benito
Keith H. Wells
Proposal 2: The ratification of Ernst & Young LLP as the Companys independent registered public accounting firm for the year ending December 31, 2011.
Proposal 3: The approval, by a non-binding vote, of the compensation of the Companys named executive officers described in the Companys proxy statement with respect to the annual meeting.
Proposal 4: The determination, by a non-binding vote, of three years as the frequency with which the Company will submit to its stockholders for approval the compensation of the Companys named executive officers.
In light of the results of the advisory vote on Proposal 4, the Company intends to submit to its stockholders for approval the compensation of the Companys named executive officers every three years, until the next required vote on the frequency of stockholder votes on the compensation of named executive officers.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|INOVIO PHARMACEUTICALS, INC.|
|Chief Financial Officer|
Date: May 18, 2011